Patient-derived xenograft models of ovarian/gynecologic tumors

L. Liang, I. Mercado-Uribe, N. Niu, Y. Jiang, W. Cheng, J. Zhang, G. B. Mills, C. Scott, A. K. Sood, J. Liu

Research output: Chapter in Book/Report/Conference proceedingChapter


Patient-derived xenografts (PDXs) have become the most promising preclinical model for gynecologic malignances, especially ovarian cancer. To generate PDX models of ovarian cancer, fresh human tumors have been injected into different sites in mouse models, including the intraovarian bursa, intraperitoneal cavity, subcutaneous tissue, gonadal fat pad, mammary fat pad, and subrenal capsule. The engraftment of first-generation ovarian cancer PDXs usually takes 2-6. months. Success rates for first-generation ovarian cancer PDXs range from 25% to 80%, depending on many factors, including the type of immunocompromised mice, tumor histotypes, and implant sites. The ovarian cancer PDXs have been shown to retain the morphologic, immunophenotypic, and genomic characteristics of original human tumors. Moreover, the predictive value of ovarian cancer PDXs has been proved by recent studies that showed concordance between chemoresponse in tumor xenografts and patients.

Original languageEnglish (US)
Title of host publicationPatient Derived Tumor Xenograft Models
Subtitle of host publicationPromise, Potential and Practice
PublisherElsevier Inc.
Number of pages15
ISBN (Electronic)9780128040614
ISBN (Print)9780128040102
StatePublished - 2017
Externally publishedYes


  • Mouse models
  • Ovarian cancer
  • Patient-derived xenograft
  • Personalized therapy
  • Preclinical models

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Patient-derived xenograft models of ovarian/gynecologic tumors'. Together they form a unique fingerprint.

Cite this